TransMedics: Numb Reaction To Extraordinary Fundamentals (NASDAQ:TMDX)

Group 1 - The organ transplant leader experienced a gain of over 10% after the Q4 report but subsequently lost that gain and more [1] - The investment strategy focuses on companies with strong qualitative attributes, purchasing them at attractive prices based on fundamentals, and holding them long-term [1] - The portfolio management approach aims to avoid losers while maximizing exposure to significant winners, often resulting in a 'Hold' rating for great companies if their growth opportunity is below a certain threshold or if downside risk is too high [1]